Iluvien™: A new sustained delivery technology for posterior eye disease

Expert Opinion on Drug Delivery

Volumn 5, Issue 9, 2008, Pages 1039-1046

  Kane, Frances E ^a   Burdan, Judith ^b   Cutino, Antonio ^a   Green, Kenneth E ^a  

^a Alimera Sciences Limited   (United States)

^b Sandpiper Communications Inc   (United States)

Author keywords

Diabetic macular edema; Fluocinolone acetonide; Intravitreal; Sustained delivery

Indexed keywords

BEVACIZUMAB; CORTICOSTEROID; DEXAMETHASONE; FLUOCINOLONE ACETONIDE; ILUVIEN; IVATION; MAGNESIUM STEARATE; MICROCRYSTALLINE CELLULOSE; PEGAPTANIB; POLYVINYL ACETATE; POLYVINYL ALCOHOL; POSURDEX; RANIBIZUMAB; SILICONE; TRIAMCINOLONE ACETONIDE; TRIESENCE; TRIVARIS; UNCLASSIFIED DRUG;

ANTERIOR EYE CHAMBER; ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; CATARACT; CLINICAL TRIAL; DIABETIC MACULAR EDEMA; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXPOSURE; DRUG IMPLANT; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG RELEASE; DRUG SAFETY; DRUG TISSUE LEVEL; ENDOPHTHALMITIS; EYE DISEASE; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR HYPOTENSION; LASER COAGULATION; LOW DRUG DOSE; NONHUMAN; OFF LABEL DRUG USE; OUTPATIENT CARE; POSTERIOR EYE CHAMBER; REVIEW; SUSTAINED RELEASE FORMULATION; UVEITIS; VITRECTOMY; DELAYED RELEASE FORMULATION; DIABETIC RETINOPATHY; RETINA MACULA EDEMA;

DELAYED-ACTION PREPARATIONS; DIABETIC RETINOPATHY; FLUOCINOLONE ACETONIDE; HUMANS; MACULAR EDEMA;

EID: 54049091605     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425247.5.9.1039     Document Type: Review

References (29)

1. Chibber R, Chibber S, Kohner E. 21st-century treatment of diabetic retinopathy. Expert Rev Endocrinol Metab 2007;2(5):623-31
2. Ciulla T, Amador A, Zinman B. Diabetic retinopathy and diabetic macular edema. Diabetes Care 2003;26(9):2653-64
3. Antcliff R, Marshall J. The pathogenesis of edema in diabetic maculopathy. Semin Ophthal 1999; 14(4):223-32
4. Kuppermann B. Understanding the pathophysiology of macular edema and molecular rationale for therapy. Ret Phys 2008;S-3-5
5. Bhavsar R. Diabetic retinopathy: the latest in current management. Retina 2006;26(6):S71-9
6. Chous P. Management of diabetic retinopathy in the 21st century. Diabetes in Control.com. Issue 389, 2007. Available from: http://www.diabetesincontrol.com/results.php?storyarticle=5263 [Last accessed 1 May 2008]
7. Lewis H. The role of vitrectomy in the treatment of diabetic macular edema. Am J Ophthal 2001;131(1):123-5
8. Macugen Diabetic Retinopathy Study Group. A phase II randomized double-masked trial of pegaptanib, and anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005;112(10):1747-57
9. Avery R, Pearlman, J, Pieramici D, et al. Intravitreal bevacizumab (avastin®) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006;113(10):1695-705
10. Lang G. Laser treatment of diabetic retinopathy. Dev Ophthalmol 2007;39:48-68
11. Kim JE, Pollack JS, Miller DG, et al.; for the ISIS Study Group. A prospective, randomized, dose escalation intravitreal steroid injection study for refractory diabetic macular edema. Retina 2008;28:735-40
12. Gillies MC, Sutter FK, Simpson JM, et al. Intravitreal triamcinolone for refractory diabetic macular edema: two-year results ofa double-masked, placebo-controlled, randomized clinical trial. Ophthalmology 2006;113(9): 1533-8
13. Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema. Br J Ophthalmol 2008;92:76-80
14. Jager RD, Aiello LP, Patel SC, Cunningham ET Jr. Risks of intravitreous injection: a comprehensive review. Retina 2004;24(5):676-98
15. Felinski E, Antonetti D. Glucocorticoid regulation of endotheliai cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res 2005;30:949-57
16. Kane FE, Green KE, Weissman A. A comparison of in vitro receptor binding of glucocorticoids [abstract 106]. Program and abstracts of the Association for Research in Vision and Ophthalmology, Annual Meeting; 2007 FL, USA
17. Driot JY, Novack GD, Rittenhouse KD, et al. Ocular pharmacokinetics of fiuocinolone acetonide after Refisert® intravitreal implantation in rabbits over a 1-year period. J Ocul Pharm Ther 2004;20:269-75
18. Pearson PA, Baker CW, Elliot D, et al. Fluocinolone acetonide intravitreal implant in subjects with diabetic macular edema: 12-month results. Presented at paper session 516 (Retina) of ARVO; 8 May 2003 [E-Abstract 4288]. Invest Ophthalmol Vis Sci 2003;44
19. DME Fluocinolone Acetonide Study Group. Fluocinolone acetonide intmvitreal implant for the treatment of DME: 12 month results from a randomized multi-center controlled dinical trial. Presented at the Retina Subspecialty Day, AAO; 2003
20. Pearson PA, Baker CW,, Elliot D, et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: 2-year results. Presentation 1111 at Symposium 220 of ARVO; 26 April 2004. Invest Ophthalmol Vis Sci 2004;45:S1111
21. Pearson P, Baker C, Eliott D, et al. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 2-year results of a multi-center dinical trial [abstract 4673]. Program and abstracts of the Association for Research in Vision and Ophthalmology. 2005 Annual Meeting; 2005; FL, USA
22. Pearson P, Levy B, Comstock T; Fluocinolone Acetonide Implant Study Group. Fluocinolone acetonide intravitreal implant to treat diabetic macular edema: 3-year results of a multi-center clinical trial [abstract # 5442]. ARVO; 2006
23. Friedrich S, Cheng YL, Saville B. Drug distribution in the vitreous humor of the human eye: the effects of intravitreal injection position and volume. Curr Eye Res 1997; 16:663-9
24. Stay M, Xu J, Randolph T, Barocas V. Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor. Pharm Res 2003;20(1):96-102 the
25. Ryan SJ, editor-in-Chief. Retina. Volume 1. In: Ogden TE, Hinton DR, editors, Basic science and inherited retinal disease. St Louis, MO: Mosby, Inc. 2001. p. 109-11
26. Park J, Bungay PM, Lutz RJ, et al. Evalution of coupled convective - diffusive transport of drugs administered by intravitreal injection and controlled release implant. J Control Release 2005;279-95
27. Welty D, Kupperman BD, Chang-Lin JE, et al. Dexamethasone posterior segment drug delivery system: pharmacokinetics in vitrectomized and non-vitrectomized eyes. Presented at ASRS; 2007
28. Lee S, D'Argenio D, Moats R, et al. Pharmacokinetic modeling to improve the design of intravitreal corticosteroid implants for treating macular edema [E-Abstract 288], ASRS; 2007. Invest Ophthalmol Vis Sci 2007
29. Mruthyunjaya P. Medidur insert technology. Ret Phys 2007;25-8